Oramed Pharmaceuticals Inc.

Major Shareholding Notification • Mar 16, 2023

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or

Instruction 1(b).

Form 5 obligations may continue. See STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Rozov Yadin		2. Issuer Name and Ticker or Trading Symbol Oramed Pharmaceuticals Inc. [ORMP]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) ____ 10% Owner X
(Last) (First) (Middle) 1185 Avenue of the Americas		3. Date of Earliest Transaction (Month/Day/Year) 03/13/2023	Director _ Officer (give title below)_ Other (specify below)
(Street) New York NY (City) (State)	10036 (Zip)	4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person ____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any	Code (Instr. 8)	3. Transaction		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form:	7. Nature of Indirect Beneficial
		(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common Stock	03/13/2023		P		20,000 (1)	A	\$1.956	36,500	D
Common Stock	03/14/2023		P		50,000 (2)	A	\$2.049	86,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction	3A. Deemed	4.								8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transaction		5. Number of		6. Date Exercisable and Expiration Date		7. Title and Amount of		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code		Derivative		(Month/Day/Year)	Underlying		Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)		Securities					Securities	(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative					Acquired					(Instr. 3 and 4)		Owned	Security:	(Instr. 4)
	Security					(A) or							Following	Direct (D)
							Disposed of						Reported	or Indirect
						(D)							Transaction(s)	(I)
						(Instr. 3, 4,							(Instr. 4)	(Instr. 4)
					and 5)
											Amount
											or
								Date	Expiration		Number
				Code	V	(A)	(D)	Exercisable	Date	Title	of Shares

Explanation of Responses:

• (1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$1.95 to \$1.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.
• (2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$2.00 to \$2.05, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.

/s/ Yadin Rozov 03/15/2023

**Signature of Reporting Person Date

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.